Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Completed × Paraproteinemias × Clear all
NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Pfizer

Phase 2 Completed
39 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Paraproteinemias, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Neoplasms, Plasma Cell, Primary Myelofibrosis